Capecitabine is an oral fluorouracil prodrug which is licenced for treatment of metastatic breast and colorectal cancer [1, 2] . Toxic effects are similar to fluorouracil and include diarrhoea and hand-foot syndrome which resolve on drug withdrawal. We report two cases of large bowel perforation associated with the start of capecitabine treatment in the setting of breast cancer.
bowel perforation in association with metastatic colorectal cancer treatment include having a primary bowel cancer in situ, recent colonoscopy or sigmoidoscopy and previous adjuvant radiotherapy [3] .
None of these risk factors were present in our patients; however, one patient did have diverticular disease which may have increased their risk of bowel perforation. There was no evidence of breast cancer in either of the surgical resection specimens to explain the perforations. Even though the precise mechanism of bowel perforation is uncertain for majority of patients, capecitabine and 5-FU have significant toxicity to colonic cells. It is therefore likely that both perforations arose in areas of bowel that were either stressed or damaged and or undergoing normal regeneration, a process that was disrupted by capecitabine treatment which may have precipitated the perforations. Although uncommon, these cases highlight a potentially serious life-threatening complication of capecitabine treatment which clinicians should be aware of. 
